Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma

New England Journal of Medicine

Volumn 319, Issue 25, 1988, Pages 1676-1680

  Rosenberg, Steven A ^a   Packard, Beverly S ^a   Aebersold, Paul M ^a   Solomon, Diane ^a   Topalian, Suzanne L ^a   Toy, Stephen T ^c   Simon, Paul ^c   Lotze, Michael T ^a   Yang, James C ^a   Seipp, Claudia A ^a   Simpson, Colleen ^a   Carter, Charles ^b   Bock, Steven ^a   Schwartzentruber, Douglas ^a   Wei, John P ^a   White, Donald E ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; INTERLEUKIN 2;

ADULT; ARTICLE; CELL CULTURE; FEMALE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE; MALE; MELANOMA; METASTASIS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; CLINICAL ARTICLE; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; CELLS, CULTURED; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; HUMAN; IMMUNOTHERAPY; INTERLEUKIN-2; LYMPHOCYTES; MALE; MELANOMA; MIDDLE AGE; NEOPLASM METASTASIS;

EID: 0024166189     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198812223192527     Document Type: Article

References (27)

1. Rosenberg S. Lymphokine-activated killer cells: a new approach to the immunotherapy of cancer. JNCI 1985; 75: 595–603.
2. Mule JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984; 225: 1487–9.
3. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwartz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 1985; 161: 1169–88.
4. Lafreniere R, Rosenberg SA. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res 1985; 45: 3735–41.
5. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485–92.
6. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA. High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity, and histologic findings. JAMA 1986; 256: 3117–24.
7. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889–97.
8. Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA. Lymphokine-activated killer cell phenomenon. II. The precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med 1983; 157: 884–97.
9. Rosenstein M, Yron I, Kaufmann Y, Rosenberg SA. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer resistant murine tumor cells by lymphocytes cultured in interleukin-2. Cancer Res 1984; 44: 1946–53.
10. Yron I, Wood TA Jr, Spiess P, Rosenberg SA. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol 1980; 125: 238–45.
11. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 223: 1318–21.
12. Spiess PJ, Yang JC, Rosenberg SA. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. JNCI 1987; 79: 1067–75.
13. Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 1987; 138: 989–95.
14. Itoh K, Tilden AB, Balch CM. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res 1986; 46: 3011–7.
15. Kurnick JT, Kradin RL, Blumberg R, Schneeberger EE, Boyle LA. Functional characterization of T lymphocytes propagated from human lung carcinomas. Clin Immunol Immunopathol 1986; 38: 367–80.
16. Rabinowich H, Cohen R, Bruderman I, Steiner Z, Klajman A. Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res 1987; 47: 173–7.
17. Miescher S, Whiteside TL, Moretta L, von Fliedner V. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J Immunol 1987; 138: 4004–11.
18. Topalian SL, Muul LM, Solomon D, Rosenberg SA. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 1987; 102: 127–41.
19. Belldegrun A, Muul LM, Rosenberg SA. Interleukin 2 expanded tumor–infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res 1988; 48: 206–14.
20. Topalian S, Solomon D, Avis FP, et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol 1988; 6: 839–53.
21. Kradin RL, Boyle LA, Preffer FI, et al. Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer. Cancer Immunol Immunother 1987; 24: 76–85.
22. Rosenberg SA, Grimm EA, McGrogan M, et al. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 1984; 223: 1412–4.
23. Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 1986; 137: 1735–42.
24. Berendt MJ, North RJ. T-cell-mediated suppression of anti-tumor immunity: an explanation for progressive growth of an immunogenic tumor. J Exp Med 1980; 151: 69–80.
25. Shu S, Rosenberg SA. Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells. J Immunol 1985; 135: 2895–903.
26. Eberlein TJ, Rosenstein M, Rosenberg SA. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med 1982; 156: 385–97.
27. Fisher B, Packard BS, Read EJ, et al. Tumor localization of adoptively transferred Indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol (in press).